Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and Debrox for ear wax removal. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; Dramamine for motion sickness relief; enemas and other laxative products under the Fleet brand name; Gaviscon for upset stomach; cough drops under the Luden's brand; Monistat for yeast infections in women; Nix for lice and parasite treatments; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; TheraTears for dry eyes; nasal saline sprays and washes under the Fess brand name; and Hydralyte for oral rehydration. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Prestige Consumer Healthcare Inc.

Pathfinder Bancorp ( ($PBHC) ) has issued an announcement. On March 30, 2026, Pathfinder Bancorp, Inc. announced that its board declared a cash div...

Pathfinder Bancorp Declares Quarterly Cash Dividend for Shareholders

ATB Cormark Capital Markets analyst Kyle McPhee maintained a Buy rating on Premium Brands on March 20 and set a price target of C$150.00. The compa...

ATB Cormark Capital Markets Sticks to Its Buy Rating for Premium Brands (PBH)

In a report released on March 20, Luke Hannan from Canaccord Genuity reiterated a Buy rating on Premium Brands, with a price target of C$123.00. Th...

Canaccord Genuity Keeps Their Buy Rating on Premium Brands (PBH)

National Bank analyst maintained a Hold rating on Premium Brands on March 20 and set a price target of C$108.00. The company’s shares closed last F...

Premium Brands (PBH) Receives a Hold from National Bank

In a report released today, from Raymond James maintained a Buy rating on Premium Brands, with a price target of C$115.00. In addition to Raymond J...

Raymond James Sticks to Their Buy Rating for Premium Brands (PBH)

In a report released today, Chris Li CFA from Desjardins maintained a Buy rating on Premium Brands, with a price target of C$120.00. According to T...

Desjardins Sticks to Their Buy Rating for Premium Brands (PBH)

In a report released today, Ty Collin from CIBC maintained a Buy rating on Premium Brands, with a price target of C$110.00. According to TipRanks, ...

CIBC Sticks to Its Buy Rating for Premium Brands (PBH)

In a report released yesterday, Ryland Conrad from RBC Capital maintained a Buy rating on Premium Brands, with a price target of C$129.00. The comp...

RBC Capital Reaffirms Their Buy Rating on Premium Brands (PBH)

Prestige Consumer Healthcare ( ($PBH) ) has provided an announcement. On March 19, 2026, Prestige Brands, Inc., a wholly owned unit of Prestige Con...

Prestige Consumer to Acquire Breathe Right Brand Portfolio

In a report released today, Luke Hannan from Canaccord Genuity reiterated a Buy rating on Premium Brands, with a price target of C$123.00. Accordin...

Market Cap	$3.08B	P/E Ratio	12.51
52W High	$89.37	52W Low	$51.28
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	1.8%	52W Position	14.4%
Overall Score	59	Value Score	80
Quality Score	63	Technical Score	36

EPS Current Est	$4.54	EPS Next Est	$4.78
EPS Growth Est	+5.3%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PBH	$56.78	+2.20%	451.86K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PBH	$56.78	+2.2%	451.86K
3
4
5
6

PBH

PBH

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Prestige Consumer Healthcare Inc. Data in Excel

Get Prestige Consumer Healthcare Inc. Data in Excel